Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 256

1.

Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.

Shelton PQ, Ivanowicz AN, Wakeman CM, Rydberg MG, Norton J, Riggs SB, Teigland CM.

Urology. 2013 May;81(5):979-84. doi: 10.1016/j.urology.2012.10.089. Epub 2013 Mar 20.

PMID:
23523297
[PubMed - indexed for MEDLINE]
2.

Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.

Ross AE, Feng Z, Pierorazio PM, Landis P, Walsh PC, Carter HB, Trock BJ, Schaeffer EM.

BJU Int. 2012 Sep;110(5):651-7. doi: 10.1111/j.1464-410X.2011.10875.x. Epub 2012 Jan 30.

PMID:
22289613
[PubMed - indexed for MEDLINE]
3.

Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.

Margel D, Nandy I, Wilson TH, Castro R, Fleshner N.

J Urol. 2013 Dec;190(6):2039-45. doi: 10.1016/j.juro.2013.06.051. Epub 2013 Jun 29.

PMID:
23820059
[PubMed - indexed for MEDLINE]
4.

Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.

Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ.

Eur Urol. 2012 Nov;62(5):757-64. doi: 10.1016/j.eururo.2012.05.025. Epub 2012 May 18.

PMID:
22658758
[PubMed - indexed for MEDLINE]
5.

The use of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican referral population: a validation study.

Liang Y, Ketchum NS, Louden C, Jimenez-Rios MA, Thompson IM, Camarena-Reynoso HR.

Urol Int. 2012;89(1):9-16. doi: 10.1159/000338270. Epub 2012 May 24.

PMID:
22626812
[PubMed - indexed for MEDLINE]
6.

Association of 5α-reductase inhibitor use and pathological features of prostate cancer in men undergoing radical prostatectomy.

Hong SK, Oh JJ, Lee S, Lee HM, Byun SS, Choe G, Lee SE.

Prostate. 2012 Aug 1;72(11):1187-92. doi: 10.1002/pros.22468. Epub 2011 Dec 7.

PMID:
22161951
[PubMed - indexed for MEDLINE]
7.

Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.

Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, Schröder FH, Roobol MJ.

BJU Int. 2012 Dec;110(11):1672-7. doi: 10.1111/j.1464-410X.2012.11434.x. Epub 2012 Aug 29.

PMID:
22928973
[PubMed - indexed for MEDLINE]
8.

Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.

Godtman RA, Holmberg E, Khatami A, Stranne J, Hugosson J.

Eur Urol. 2013 Jan;63(1):101-7. doi: 10.1016/j.eururo.2012.08.066. Epub 2012 Sep 5.

PMID:
22980443
[PubMed - indexed for MEDLINE]
9.

Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.

Helfand BT, Blackwell RH, McVary KT.

J Urol. 2010 Jul;184(1):218-23. doi: 10.1016/j.juro.2010.03.020. Epub 2010 May 16.

PMID:
20483154
[PubMed - indexed for MEDLINE]
10.

Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.

Marberger M, Freedland SJ, Andriole GL, Emberton M, Pettaway C, Montorsi F, Teloken C, Rittmaster RS, Somerville MC, Castro R.

BJU Int. 2012 Apr;109(8):1162-9. doi: 10.1111/j.1464-410X.2011.10373.x. Epub 2011 Jun 23.

PMID:
21699645
[PubMed - indexed for MEDLINE]
11.

Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.

Iremashvili V, Manoharan M, Rosenberg DL, Soloway MS.

BJU Int. 2013 Apr;111(4):574-9. doi: 10.1111/j.1464-410X.2012.11127.x. Epub 2012 May 4.

PMID:
22564446
[PubMed - indexed for MEDLINE]
12.

PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.

Kaplan SA, Roehrborn CG, Meehan AG, Liu KS, Carides AD, Binkowitz BS, Heyden NL, Vaughan ED Jr.

Urology. 2009 May;73(5):935-9. doi: 10.1016/j.urology.2008.09.079. Epub 2009 Mar 28.

PMID:
19328538
[PubMed - indexed for MEDLINE]
13.

Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies.

van Leeuwen PJ, Kölble K, Huland H, Hambrock T, Barentsz J, Schröder FH.

Eur Urol. 2011 Feb;59(2):183-90. doi: 10.1016/j.eururo.2010.09.035. Epub 2010 Dec 4. Review.

PMID:
21130560
[PubMed - indexed for MEDLINE]
14.

Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program.

Bul M, van den Bergh RC, Rannikko A, Valdagni R, Pickles T, Bangma CH, Roobol MJ.

Eur Urol. 2012 Feb;61(2):370-7. doi: 10.1016/j.eururo.2011.06.027. Epub 2011 Jun 24.

PMID:
21704447
[PubMed - indexed for MEDLINE]
15.

Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5α-reductase inhibitors markedly enhances the detection rate of prostate cancer.

Kaplan SA, Lee RK, Chung DE, Te AE, Scherr DS, Tewari A, Vaughan ED.

J Urol. 2012 Sep;188(3):757-61. doi: 10.1016/j.juro.2012.04.111. Epub 2012 Jul 19.

PMID:
22818135
[PubMed - indexed for MEDLINE]
16.

Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.

Krakowsky Y, Loblaw A, Klotz L.

J Urol. 2010 Jul;184(1):131-5. doi: 10.1016/j.juro.2010.03.041. Epub 2010 May 15.

PMID:
20478589
[PubMed - indexed for MEDLINE]
17.

Role of immediate confirmatory prostate biopsy to ensure accurate eligibility for active surveillance.

Motamedinia P, RiChard JL, McKiernan JM, DeCastro GJ, Benson MC.

Urology. 2012 Nov;80(5):1070-4. doi: 10.1016/j.urology.2012.07.049.

PMID:
23107398
[PubMed - indexed for MEDLINE]
18.
19.
20.

Effect of dutasteride on the risk of prostate cancer.

Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS; REDUCE Study Group.

N Engl J Med. 2010 Apr 1;362(13):1192-202. doi: 10.1056/NEJMoa0908127.

PMID:
20357281
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk